Effect of anti-IL-13 treatment on airway dimensions in severe asthma: Subgroup analysis

Christopher E. Brightling (Leicester, United Kingdom), Christopher E. Brightling, Lars H. Nordenmark, Meena Jain, Edward Piper, Dewei She, Martin Braddock, Gene Colice, Göran Tornling

Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Session: New targets and modalities for the treatment of asthma and COPD
Session type: Poster Discussion
Number: 2119
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Christopher E. Brightling (Leicester, United Kingdom), Christopher E. Brightling, Lars H. Nordenmark, Meena Jain, Edward Piper, Dewei She, Martin Braddock, Gene Colice, Göran Tornling. Effect of anti-IL-13 treatment on airway dimensions in severe asthma: Subgroup analysis. Eur Respir J 2015; 46: Suppl. 59, 2119

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Cost-effectiveness of bronchial thermoplasty (BT) treatment relative to no BT treatment option for patients with severe asthma
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014

Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014


Experience with omalizumab in patients with moderate and severe asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


As-needed formoterol (F) in asthma: An analysis of the East-Asian subgroup of the RELIEF study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Adherence to the treatment of patients with bronchial asthma
Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage?
Year: 2015


P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients
Source: International Congress 2016 – Asthma management
Year: 2016

Bronchial thermoplasty in patients with very severe asthma: Safety and clinical outcomes
Source: International Congress 2016 – Airway stenting and ablation
Year: 2016


Evaluation of methotrexate in the treatment of severe asthma
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015


Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013


Improved effects of aerosol-type fluticasone propionate/formoterol combination on residual asthmatic inflammation in distal airways of patients with moderate asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Effects of beta-blockers on lung function in bronchial asthma patients
Source: International Congress 2014 – Asthma or COPD: comorbid condition or a poorly understood single disease?
Year: 2014

Evaluation of vitamin D in asthma: Its effect on inflammatory markers and clinical profile
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015

Asthma control, symptoms and exacerbations across treatment levels in patients with asthma
Source: Annual Congress 2013 –Management of respiratory diseases in primary care
Year: 2013


Improved effects of formoterol-budesonide combination on residual eosinophilic inflammation in asthmatic peripheral airway
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013


Efficacy of carbamazepine in treatment of bronchial asthma
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013


LATE-BREAKING ABSTRACT: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: the SIRIUS study
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014

The influence of bronchial asthma as a comorbidity of COPD on the COPD assessment test (CAT)
Source: International Congress 2014 – Asthma or COPD: comorbid condition or a poorly understood single disease?
Year: 2014


Clinical effectiveness of anti-IgE therapy in allergic severe asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Monitoring of airway resistance (Raw) in exacerbation of asthma
Source: Annual Congress 2013 –Monitoring lung function in airway diseases
Year: 2013


Acute radiological abnormalities after bronchial thermoplasty (BT)
Source: International Congress 2015 – Bronchoscopic treatment of COPD and asthma: valves, coils, thermoplastics and something more
Year: 2015